INTERACTION REGISTRY AVAILABLE

OCTOBER 01, 2007
Anna D. Garrett, PharmD, BCPS, CPP

The use of dietary supplements has risen significantly in the past decade. Unlike prescription drug products, dietary supplements are not tested for safety, efficacy, dosing requirements, or drug interactions prior to marketing, so little is known about the risk of using these products in patients taking warfarin or other oral anticoagulants.

The ClotCare International Registry of Interactions Between Oral Anticoagulants and Dietary Supplements is now available online for clinicians to report suspected interactions between supplements and anticoagulants. Likelihood of the suspected interaction will be assessed using a modification of the Naranjo Adverse Drug Reaction Probability Scale. The data that are collected from this project can be used as a guide for clinicians regarding the safety of certain products in patients taking oral anticoagulants.

ClotCare, the sponsoring entity for the registry, is asking clinicians to begin reporting observed interactions between warfarin and dietary or herbal supplements. The System will ask the reporting clinician to check responses to several questions in order to grade the strength of the data being reported. Development is currently under way to make the registry searchable so that reported cases may be reviewed by others. Information about the registry, Including how to register to report an interaction, can be found at www.clotcare.com/clotcare/warfarinherbalregistry.aspx.



SHARE THIS SHARE THIS
0
 

The Oncology Care Pharmacist in Health-System Pharmacy 
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.


 

Pharmacy Times Strategic Alliance
 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.